viewNemaura Medical Inc

Nemaura executive touts sugarBEAT continuous glucose monitor at virtual diabetes conference

VP Fred Schaebsdau showcased the company’s non-invasive continuous glucose monitor and discussed the BEATdiabetes ecosystem, which helps patients manage diabetes

Nemaura graphic
Nemaura’s SugarBEAT device has already received its CE mark from regulators in Europe and is currently in production in the UK

Nemaura Medical Inc (NASDAQ:NMRD) announced Tuesday that its vice president of Straategy and Strategic Alliances Fred Schaebsdau was a guest speaker at the DiabetesMine D-Data Virtual ExChange.

Schaebsdau showcased sugarBEAT, the company’s non-invasive continuous glucose monitor (CGM) for patients with Type 2 diabetes. He also discussed the companion BEATdiabetes ecosystem, which is designed to support patients in managing their condition.

The presentation underscored the versatility of the platform for continuous non-invasive monitoring, which includes temperature monitoring as well as lactate or alcohol monitoring.

READ: Nemaura Medical set to enjoy investor attention as it qualifies to join the Russell 2000 and Russell 3000 Indexes

Nemaura’s CGM can help Type 2 and pre-diabetic patients achieve better time-in-range,that is within recommended blood sugar levels, which subsequently can lead to better medical outcomes - all without requiring patients to prick their fingers.

The DiabetesMine event is held biannually. Last week’s iteration was timed to coincide with the American Diabetes Association’s Scientific Sessions, attracting a large number of attendees, including diabetes advocates, pharma leaders, developers, clinicians and others.

Nemaura’s SugarBEAT device has already received its CE mark from regulators in Europe and is currently in production in the UK.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Nemaura Medical Inc

Price: 5.76 USD

Market: NASDAQ
Market Cap: $131.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...



Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read